Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug to see if it is safe and effective for people with sickle cell disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many sites are currently utilized to conduct this experiment?
"Currently, 10 different clinical trial sites are enrolling patients; three of these being in Chapel Hill, Atlanta and Baltimore. To reduce the burden associated with travelling to participate, it is advised that you select a site closest to your residence."
What is the total recruitment size of this clinical trial?
"This trial necessitates that 40 fitting applicants must be recruited. They can join from different testing facilities, such as the University of North carolina at Chapel Hill in Chapel Hill and Visionaries Research in Atlanta."
Is this medical trial currently registering participants?
"The current status of the trial, as reported on clinicaltrials.gov, is that it is actively recruiting for participants. This medical experiment was initially posted back in December 2021 and has had its details revised most recently in October 2022."
What safety parameters must patients meet to take FTX-6058 oral capsules?
"As this is a Phase 1 trial with limited data supporting safety and efficacy, our experts at Power assigned FTX-6058 capsules a score of 1 on their risk assessment scale."
What are the primary aims of this experiment?
"This clinical trial, which has a maximal duration of 15 weeks, is aimed at assessing the concentration of FTX-6058 in plasma. Secondary objectives include tracking changes from baseline in fetal hemoglobin through HPLC, percentage reticulocytes with flow cytometry and absolute reticulocyte count via microscopy/cytometry."
Am I eligible to be a subject in this experiment?
"This clinical trial requires 40 participants with anemia and sickle cell between the ages of 18 and 65 to meet specified criteria, including a documented HbF ≤ 20%, total hemoglobin ≥ 5.5 g/dL (males) or ≤ 10.6 g/dL (females), 0-6 Vaso-Occlusive Crisis episodes in 12 months prior to screening, BMI between 18 and 32 kg/m2, Signed informed consent form before any study procedures are performed, Highly effective methods of contraception for 90 days after last dose if female or male respectively, Documented SCD at time of screening confirmed through medical"
Are persons above the age of 40 able to partake in this trial?
"The eligibility for this trial has a strict age restriction, with the minimum being 18 years old and the maximum 65."
Share this study with friends
Copy Link
Messenger